Abstract
Background: As per global guidelines, the present approach to treating bronchiectasis is to reduce additional harm to the airways by reducing inflammation and infection and enhancing airway clearance. The aim of this study was to compare the quality of life and hospitalization rates of individuals with bronchiectasis between positive expiratory pressure and other methods for airway clearance. Method: Following the PRISMA guideline (9), this systematic review investigation was carried out. We looked through the electronic databases of PubMed, Google Scholar, and Cochrane for randomized controlled studies comparing the use of prescription PEP therapy to alternative ACTs for patients with stable or acute exacerbations of bronchiectasis. We focused on English-language publications that were released between 2003 and 2016. Result: Included in this systematic review were four studies that were published between 2003 and 2015. Three studies involved individuals in clinical stability, while one study included adults experiencing a sudden exacerbation of bronchiectasis. According to the inclusion criteria, bronchiectasis was determined by HRCT in two investigations and by medical diagnosis in the other two studies. Conclusion: PEP therapy appears to have comparable effects to other ACTs on dyspnea symptoms, health-related Qol, and sputum expectoration when administered in a stable clinical state or during an acute exacerbation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
